Dashboard
Manage Tickers

PKIRevvity Inc.


$ 108.27 $ 2.10 (1.98 %)    

Thursday, 16-May-2024 14:30:13 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 452.72 $ -0.75 (-0.17 %)
DIA $ 399.69 $ 0.05 (0.01 %)
SPY $ 529.59 $ -0.34 (-0.06 %)
TLT $ 92.05 $ -0.34 (-0.37 %)
GLD $ 220.21 $ 0.20 (0.09 %)
$ 107.31
$ 106.17
$ 108.20 x 100
$ 108.42 x 127
$ 106.17 - $ 109.61
$ 79.39 - $ 131.69
1,477,389
na
na
$ 0.90
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

analyst-ratings-for-revvity
Analyst Ratings for Revvity
05/15/2023 15:00:26

citigroup-maintains-buy-on-revvity-lowers-price-target-to-160
Citigroup Maintains Buy on Revvity, Lowers...
05/15/2023 10:51:07

Citigroup analyst Patrick Donnelly maintains Revvity (NYSE:PKI) with a Buy and lowers the price target from $170 to $160.

stifel-maintains-hold-on-revvity-lowers-price-target-to-135
Stifel Maintains Hold on Revvity, Lowers P...
05/12/2023 11:34:34

Stifel analyst Daniel Arias maintains Revvity (NYSE:PKI) with a Hold and lowers the price target from $145 to $135.

baird-maintains-outperform-on-revvity-lowers-price-target-to-165
Baird Maintains Outperform on Revvity, Low...
05/12/2023 11:14:20

Baird analyst Catherine Schulte maintains Revvity (NYSE:PKI) with a Outperform and lowers the price target from $182 to $165.

barclays-maintains-equal-weight-on-revvity-lowers-price-target-to-125
Barclays Maintains Equal-Weight on Revvity...
05/12/2023 10:11:56

Barclays analyst Luke Sergott maintains Revvity (NYSE:PKI) with a Equal-Weight and lowers the price target from $140 to $125.

why-revvity-shares-are-falling-today
Why Revvity Shares Are Falling Today
05/11/2023 14:03:56

earnings-scheduled-for-may-11-2023
Earnings Scheduled For May 11, 2023
05/11/2023 13:58:54

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. •...

for-fy23-revvity-forecasts-sales-of-290b-294b-compared-to-prior-guidance-of-294b-and-consensus-of-295b-sees-adjusted-eps-of-485-505-compared-to-prior-guidance-of-505-and-consensus-of-511
For FY23, Revvity Forecasts Sales Of $2.90...
05/11/2023 10:18:12

revvity-q1-earnings-insights
Revvity: Q1 Earnings Insights
05/11/2023 10:05:25

revvity-q1-adjusted-eps-101-misses-106-estimate-sales-67487m-miss-75104m-estimate
Revvity Q1 Adjusted EPS $1.01 Misses $1.06...
05/11/2023 10:02:21

Revvity (NYSE:PKI) reported quarterly earnings of $1.01 per share which missed the analyst consensus estimate of $1.06 by 4.72 ...

earnings-outlook-for-revvity
Earnings Outlook For Revvity
05/10/2023 15:01:07

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
04/20/2023 17:35:31

perkinelmers-oxford-immunotec-secures-new-approval-from-us-fda-expanding-instrumentation-for-latent-tuberculosis-detection-workflow
PerkinElmer's Oxford Immunotec Secures New...
03/23/2023 12:06:04

PerkinElmer's Oxford Immunotec Secures New Approval from U.S. FDA Expanding Instrumentation for Latent Tuberculosis Detecti...

earnings-scheduled-for-march-2-2023
Earnings Scheduled For March 2, 2023
03/02/2023 09:37:02

Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue ...

this-analyst-with-90-accuracy-rate-sees-over-26-upside-in-globalfoundries---5-stock-picks-from-wall-streets-most-accurate-analysts
This Analyst With 90% Accuracy Rate Sees O...
02/21/2023 11:44:21

US stocks closed mixed on Friday, with the Dow Jones gaining more than 100 points during the session.

credit-suisse-reiterates-neutral-on-perkinelmer-maintains-160-price-target
Credit Suisse Reiterates Neutral on Perkin...
02/15/2023 13:38:12

Credit Suisse analyst Dan Leonard reiterates PerkinElmer (NYSE:PKI) with a Neutral and maintains $160 price target.

baird-maintains-outperform-on-perkinelmer-lowers-price-target-to-182
Baird Maintains Outperform on PerkinElmer,...
02/15/2023 12:26:49

Baird analyst Catherine Schulte maintains PerkinElmer (NYSE:PKI) with a Outperform and lowers the price target from $185 to ...

perkinelmer-enters-next-chapter-in-2023-q4-earnings-beat-street-expectations
PerkinElmer Enters Next Chapter In 2023, Q...
02/14/2023 15:42:19

correction-perkinelmer-q4-combined-revenue-109b-beat-104b-estimate
CORRECTION: PerkinElmer Q4 Combined Revenu...
02/14/2023 11:20:34

perkinelmer-forecasts-fy23-revenue-of-294b-and-adjusted-eps-of-505-compared-to-consensus-of-358b-and-586-the-guidance-assumes-no-contribution-from-covid-related-revenues
PerkinElmer Forecasts FY23 Revenue Of $2.9...
02/14/2023 11:04:50

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION